Results 21 to 30 of about 282,918 (268)

Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights

Journal of Hepatocellular Carcinoma, 2023
James Yu,1 Robin Park,1 Richard Kim2 1Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2Department of Gastrointestinal Oncology, H.
Yu J, Park R, Kim R
doaj  

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer

Frontiers in Pharmacology, 2022
Background: Anlotinib is a novel anti-angiogenesis drug. In non-small cell lung cancer (NSCLC), high body mass index (BMI) was not associated with worse survival in patients treated with bevacizumab compared with those with normal or low BMI. However, it
Anning Xiong, Wei Nie, Lei Cheng, Hua Zhong, Tianqing Chu, Runbo Zhong, Jun Lu, Shuyuan Wang, Jianlin Xu, Yinchen Shen, Feng Pan, Baohui Han, Xueyan Zhang   +12 more
doaj   +1 more source

Cancer Diagnostic and Predictive Biomarkers [PDF]

BioMed Research International, 2014
The new high-throughput “omics” technologies have recently opened the possibility to identify molecular changes and metabolic pathways in each cancer type with the possibility of molecular tumor subclassification and identification of a more reliable prognosis and appropriate treatment [1–3].
Franco M. Buonaguro, David Pauza, Maria Lina Tornesello, Pierre Hainaut, Renato Franco, Francesco M. Marincola   +5 more
openaire   +2 more sources

Clinical utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer

Frontiers in Oncology, 2014
The advent of rationally targeted therapies such as small-molecule tyrosine kinase inhibitors (TKIs) has considerably transformed the therapeutic management of a subset of patients with non-small cell lung cancer (NSCLC) harboring defined molecular ...
Vincent eFaugeroux, Vincent eFaugeroux, Emma ePailler, Emma ePailler, Nathalie eAuger, Meilissa eTaylor, Meilissa eTaylor, Françoise eFarace, Françoise eFarace   +8 more
doaj   +1 more source

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

Molecular Oncology, 2020
Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response.
Thomas Urup, Linn Gillberg, Katja Kaastrup, Maya Jeje Schuang Lü, Signe Regner Michaelsen, Vibeke Andrée Larsen, Ib Jarle Christensen, Helle Broholm, Ulrik Lassen, Kirsten Grønbæk, Hans Skovgaard Poulsen   +10 more
doaj   +1 more source

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial

Molecular Oncology, 2022
As most erb‐b2 receptor tyrosine kinase 2 (HER2)‐positive breast cancer (BC) patients currently receive dual HER2‐targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salvage ...
Tiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, Tadeusz Pienkowski, Young‐Hyuck Im, Giulia Valeria Bianchi, Barbara Galbardi, Matteo Dugo, Loris De Cecco, Ling‐Ming Tseng, Mei‐Ching Liu, Begoña Bermejo, Vladimir Semiglazov, Giulia Viale, Juan de laHaba‐Rodriguez, Do‐Youn Oh, Brigitte Poirier, Pinuccia Valagussa, Luca Gianni, Elda Tagliabue   +19 more
doaj   +1 more source

Predictive Biomarkers in Thyroid Cancer

Frontiers in Oncology, 2022
In molecular pathology, predictive biomarkers identify which patients are likely to respond to targeted drugs. These therapeutic agents block specific molecules directly involved in cancer growth, dedifferentiation and progression. Until few years ago, the only targeted drugs available for advanced thyroid cancer included multi-tyrosine kinase ...
Macerola, Elisabetta, Poma, Anello Marcello, Vignali, Paola, Proietti, Agnese, Ugolini, Clara, Torregrossa, Liborio, Basolo, Alessio, Elisei, Rossella, Santini, Ferruccio, Basolo, Fulvio   +9 more
openaire   +4 more sources

Biomarkers to Predict Antidepressant Response [PDF]

Current Psychiatry Reports, 2010
During the past several years, we have achieved a deeper understanding of the etiology/pathophysiology of major depressive disorder (MDD). However, this improved understanding has not translated to improved treatment outcome. Treatment often results in symptomatic improvement, but not full recovery.
Leuchter, Andrew F., Cook, Ian A., Hamilton, Steven P., Narr, Katherine L., Toga, Arthur, Hunter, Aimee M., Faull, Kym, Whitelegge, Julian, Andrews, Anne M., Loo, Joseph, Way, Baldwin, Nelson, Stanley F., Horvath, Steven, Lebowitz, Barry D.   +13 more
openaire   +5 more sources

Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer

Frontiers in Pharmacology, 2019
ZNF217 is a candidate oncogene with a wide variety of deleterious functions in breast cancer. Here, we aimed at investigating in a pilot prospective study the association between ZNF217 mRNA expression levels and the clinical response to neoadjuvant ...
Julie A. Vendrell, Jérôme Solassol, Jérôme Solassol, Balázs Győrffy, Balázs Győrffy, Paul Vilquin, Marta Jarlier, Caterina F. Donini, Laurent Gamba, Thierry Maudelonde, Philippe Rouanet, Pascale A. Cohen   +11 more
doaj   +1 more source

Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer

Molecular & Cellular Oncology, 2020
Deciphering principles of inter-tumoral heterogeneity is crucial for refinement of precision oncology. We have recently demonstrated that ‘oncogenic cooperation‘ between somatic mutations and regulatory germline variants can serve as a major cause for ...
Julian Musa, Thomas G. P. Grünewald
doaj   +1 more source